AU2019293530B2 - Anti-L1CAM antibodies and uses thereof - Google Patents
Anti-L1CAM antibodies and uses thereofInfo
- Publication number
- AU2019293530B2 AU2019293530B2 AU2019293530A AU2019293530A AU2019293530B2 AU 2019293530 B2 AU2019293530 B2 AU 2019293530B2 AU 2019293530 A AU2019293530 A AU 2019293530A AU 2019293530 A AU2019293530 A AU 2019293530A AU 2019293530 B2 AU2019293530 B2 AU 2019293530B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- antibody
- less
- antigen
- l1cam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2018-0075955 | 2018-06-29 | ||
| KR1020180075955A KR20200002451A (ko) | 2018-06-29 | 2018-06-29 | 인간 l1cam 단백질에 특이적으로 결합하는 항체 및 이의 용도 |
| US201962865871P | 2019-06-24 | 2019-06-24 | |
| US62/865,871 | 2019-06-24 | ||
| PCT/IB2019/055472 WO2020003210A1 (en) | 2018-06-29 | 2019-06-27 | Anti-l1cam antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019293530A1 AU2019293530A1 (en) | 2021-01-21 |
| AU2019293530B2 true AU2019293530B2 (en) | 2025-10-09 |
Family
ID=69154626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019293530A Active AU2019293530B2 (en) | 2018-06-29 | 2019-06-27 | Anti-L1CAM antibodies and uses thereof |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP7527007B2 (https=) |
| KR (2) | KR20200002451A (https=) |
| CN (1) | CN112689644B (https=) |
| AU (1) | AU2019293530B2 (https=) |
| CA (1) | CA3104252A1 (https=) |
| SG (1) | SG11202012680TA (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240091226A (ko) * | 2021-11-03 | 2024-06-21 | 큐론 바이오파마슈티칼 (상하이) 컴퍼니, 리미티드 | 신규 항 l1cam 항체 |
| CN115078738A (zh) * | 2022-06-30 | 2022-09-20 | 复旦大学 | 一种l1cam蛋白n979位点特异性核心岩藻糖基化的抑制剂的应用 |
| TW202417057A (zh) * | 2022-10-26 | 2024-05-01 | 大陸商同潤生物醫藥(上海)有限公司 | 人源化的l1cam抗體藥物偶聯物 |
| EP4615580A1 (en) * | 2022-11-09 | 2025-09-17 | CIS Biopharma AG | Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications |
| CN118725118B (zh) * | 2024-09-02 | 2024-11-22 | 北京凯祥弘康生物科技有限公司 | 抗人l1cam蛋白的抗体4d3 |
| CN118725119B (zh) * | 2024-09-02 | 2024-11-19 | 北京凯祥弘康生物科技有限公司 | 一种抗l1cam蛋白的抗体 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150344571A1 (en) * | 2012-11-16 | 2015-12-03 | Kangwon National University University-Industry Cooperation Foundation | Antibody binding specifically to human and mouse l1cam protein, and use therefor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007114550A1 (en) | 2006-04-03 | 2007-10-11 | Korea Research Institute Of Bioscience And Biotechnology | A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same |
| KR101501736B1 (ko) * | 2008-12-05 | 2015-03-12 | 한국생명공학연구원 | 인간 및 마우스에서 발현하는 l1cam에 특이적으로 결합하는 재조합 단일클론항체 및 그 이용 |
| KR102058381B1 (ko) * | 2012-08-24 | 2019-12-24 | 강원대학교산학협력단 | 인간 l1cam에 대한 인간화 항체 및 그의 제조 방법 |
-
2018
- 2018-06-29 KR KR1020180075955A patent/KR20200002451A/ko active Pending
-
2019
- 2019-06-27 CN CN201980045545.5A patent/CN112689644B/zh active Active
- 2019-06-27 KR KR1020217003012A patent/KR102929858B1/ko active Active
- 2019-06-27 CA CA3104252A patent/CA3104252A1/en active Pending
- 2019-06-27 JP JP2020573334A patent/JP7527007B2/ja active Active
- 2019-06-27 AU AU2019293530A patent/AU2019293530B2/en active Active
- 2019-06-27 SG SG11202012680TA patent/SG11202012680TA/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150344571A1 (en) * | 2012-11-16 | 2015-12-03 | Kangwon National University University-Industry Cooperation Foundation | Antibody binding specifically to human and mouse l1cam protein, and use therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019293530A1 (en) | 2021-01-21 |
| CN112689644A (zh) | 2021-04-20 |
| CA3104252A1 (en) | 2020-01-02 |
| CN112689644B (zh) | 2025-01-28 |
| SG11202012680TA (en) | 2021-01-28 |
| KR102929858B1 (ko) | 2026-02-26 |
| JP7527007B2 (ja) | 2024-08-02 |
| KR20210042091A (ko) | 2021-04-16 |
| JP2021529776A (ja) | 2021-11-04 |
| KR20200002451A (ko) | 2020-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019293530B2 (en) | Anti-L1CAM antibodies and uses thereof | |
| CN112912397B (zh) | 抗cd3抗体及其用途 | |
| ES2791249T3 (es) | Agentes de enlace CD123 y sus utilizaciones | |
| CN107001476B (zh) | 用于增强的免疫应答和癌症治疗的组合物和方法 | |
| US12509513B2 (en) | Anti-L1CAM antibodies and uses thereof | |
| CN116333133A (zh) | 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途 | |
| RU2770620C1 (ru) | Связывающие молекулы, вызывающие клеточную активацию | |
| CN117964756A (zh) | 抗序列相似家族19成员a5的抗体及其使用方法 | |
| KR20220117267A (ko) | Tgf-베타-rii 결합 단백질 | |
| JP2022505144A (ja) | Her2 s310f特異的な抗原結合分子 | |
| CN117098781A (zh) | 靶向cd22和cd79b的抗体 | |
| CN111788229A (zh) | Csf1r结合剂 | |
| KR20230060531A (ko) | Pd-1에 결합하는 항체 및 이의 용도 | |
| HK40125826A (zh) | 抗l1cam抗体及其用途 | |
| EA048894B1 (ru) | Антитела к l1cam и их применение | |
| HK40121247A (zh) | 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途 | |
| HK40126767A (zh) | 抗cd3抗体及其用途 | |
| WO2025237392A1 (zh) | 新型抗egfr抗体、药物偶联物及其用途 | |
| HK40101884A (zh) | 靶向cd22和cd79b的抗体 | |
| HK40096481A (zh) | 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途 | |
| BR122023027661A2 (pt) | Proteínas de ligação de tgf-beta-rii | |
| HK40052977A (en) | Anti-cd3 antibodies and uses thereof | |
| EA044685B1 (ru) | Антитела к gprc5d, биспецифические антигенсвязывающие молекулы, которые связывают gprc5d и cd3, и их применение | |
| HK1240948B (zh) | Cd123结合剂及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: APITBIO, INC. Free format text: FORMER APPLICANT(S): KANGWON NATIONAL UNIVERSITY UNIVERSITY-INDUSTRY COOPERATION FOUNDATION |
|
| FGA | Letters patent sealed or granted (standard patent) |